Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaginal use of estradiol is associated with a reduced risk of rectal cancer in postmenopausal women: A Finnish nationwide case-control study.

Maturitas·2025
Same author

Female Adipose Tissue Sex Steroid Biosynthesis.

Seminars in reproductive medicine·2025
Same author

Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Injection for Stress Urinary Incontinence - 5-Year Follow-Up.

NEJM evidence·2025
Same author

Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Bulking Agent for Stress Urinary Incontinence: Patient Choice and Outcomes in Finland.

International urogynecology journal·2025
Same author

Update of the impact of menopausal hormone therapy on breast cancer risk.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Frequent Use of Premenopausal Progestin in Women With Prior Preeclampsia.

The Journal of clinical endocrinology and metabolism·2024

Related Experiment Video

Updated: Jul 2, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Progestogens in Menopausal Hormone Therapy: A Double-Edged Sword.

Olavi Ylikorkala1, Johanna M Joensuu1, Heli Siitonen1

  • 1Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.

Seminars in Reproductive Medicine
|May 16, 2025
PubMed
Summary

Progestogens protect the endometrium but increase breast cancer and deep vein thrombosis risks. Continuous use offers the best protection, with some progestogens potentially being safer regarding breast cancer risk.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
05:32

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Related Experiment Videos

Last Updated: Jul 2, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
05:32

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Area of Science:

  • Reproductive Medicine
  • Gynecology
  • Endocrinology

Background:

  • Estrogen therapy for menopausal symptoms requires endometrial protection.
  • Progestogens are commonly added to estrogen to prevent endometrial hyperplasia and cancer.
  • Various progestogens and administration routes exist, each with unique profiles.

Purpose of the Study:

  • To review the efficacy and safety of different progestogens used with estrogen for endometrial protection.
  • To evaluate the impact of progestogens on breast cancer risk, thrombosis, and other health outcomes.
  • To assess the optimal use of progestogens for endometrial safety.

Main Methods:

  • Systematic review of progestogens (norethisterone acetate, medroxyprogesterone acetate, dydrogesterone, micronized progesterone, levonorgestrel, drospirenone, trimegestone) used with estrogen.
  • Analysis of administration routes (oral, vaginal, transdermal, intrauterine) and usage patterns (sequential, continuous).
  • Evaluation of data on breast cancer risk, deep vein thrombosis (DVT), colorectal cancer, vascular health, and neurodegenerative diseases.

Main Results:

  • Continuous progestogen use provides the most effective endometrial protection.
  • Progestogen addition significantly elevates breast cancer risk; dydrogesterone, micronized progesterone, and levonorgestrel intrauterine devices may be associated with lower risk.
  • Progestogens double DVT risk and diminish estrogen's benefits for colorectal cancer and vascular health, while potentially decreasing vascular dementia risk.

Conclusions:

  • Progestogens are effective for endometrial protection but carry significant risks, including increased breast cancer and DVT.
  • The choice of progestogen and administration route impacts safety profiles.
  • Further research into low-dose unopposed estrogen regimens, with careful endometrial monitoring, is warranted.